2,022 results on '"Majhail, Navneet"'
Search Results
52. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
53. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblast Leukemia: A Systematic Review
54. Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation
55. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
56. Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation
57. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis
58. Early de-escalation of antibiotic therapy in hospitalized cellular therapy adult patients with febrile neutropenia
59. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
60. Programmatic Data Analyst Continuous Process Improvement (CPI) Tracking within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN)
61. Outpatient Administration of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (NHL), in a Large Multi-Center Network
62. Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy Network
63. A Standardized Cell Dose to Optimize Unrelated Donor Peripheral Blood Stem Cell (PBSC) Collections: A Prospective Study between the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) and the National Marrow Donor Program (NMDP)
64. Centralized Data Management Model within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN)- Process, Challenges and Benefits
65. Creating a Standardized Report to Optimize Review of Internal CIBMTR Audits across a Large Multi-Center Network
66. Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy
67. Remote Patient Monitoring (RPM) Technology with Centralized Virtual Nurse Monitoring for Safe Delivery of Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapy across Multiple Sarah Cannon Transplant and Cellular Therapy Network Programs
68. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
69. A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease
70. Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships
71. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
72. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations
73. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors
74. To D or not to D: vitamin D in hematopoietic cell transplantation
75. Age and gender differences in financial distress among hematopoietic cell transplant survivors
76. Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints
77. Engaging hematopoietic cell transplantation patients and caregivers in the design of print and mobile application individualized survivorship care plan tools
78. Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach
79. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults
80. New Cancers after Autotransplantations for Multiple Myeloma
81. Long-Term Follow-Up Program
82. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy
83. Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis
84. Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
85. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation
86. Allogeneic Transplant Overview and Matched Related Donor Transplant
87. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
88. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
89. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities
90. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era
91. Graft-Versus-Host Disease and Quality of Life: Can We Make a Difference?
92. Allogeneic Transplant Overview and Matched Related Donor Transplant
93. Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation
94. Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors
95. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
96. Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study
97. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma
98. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
99. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors
100. Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.